RE:TIGIT class of checkpoint inhibitors fails with Keytruda May 13, 2024 - Merck ends Phase III Anti-Tigit + Keytruda melanoma study with high dropouts.
The late-stage study was evaluating vibostolimab as an adjuvant treatment to Keytruda in patients with resected, high-risk melanoma.
https://www.biospace.com/article/merck-halts-phase-iii-anti-tigit-keytruda-skin-cancer-study-with-high-dropouts-/